Education
About Us
Working with TipRanks
Follow Us
Medpace Holdings Inc (MEDP)
:MEDP
MEDP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$302.01 - $459.77
Previous CloseN/A
Volume64.09K
Average Volume (3M)370.34K
Market Cap
$9.52B
Enterprise Value$10.07B
Total Cash (Recent Filing)$669.44M
Total Debt (Recent Filing)$126.23M
Price to Earnings (P/E)24.7
Beta1.32
Next Earnings
Apr 21, 2025EPS Estimate
3.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)12.63
Shares Outstanding30,466,806
10 Day Avg. Volume362,725
30 Day Avg. Volume370,340
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)N/A
Price to Sales (P/S)4.68
Price to Cash Flow (P/CF)13.00
P/FCF Ratio13.00
Enterprise Value/Market Cap1.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit15.34
Enterprise Value/Ebitda21.19
Forecast
1Y Price Target
$352.67Price Target Upside12.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
---
Medpace Holdings News
PremiumCompany Announcements
Medpace Reports Revenue and Income Growth in 2024
PremiumCompany Announcements
Medpace Holdings: Navigating Growth and Challenges in 2025
---
Bulls Say, Bears Say
Bulls Say
Outsourcing EfficiencyMedpace's full service outsourcing offerings enable smaller biotech and biopharma companies to run clinical trials in the most cost- and time-efficient manner.
Pipeline AlignmentMedpace is nicely aligned to growing disease categories including oncology, metabolic, and cardiovascular, which are well-positioned for ongoing pipeline strength.
Bears Say
Clinical Trial SlowdownMedpace's growth trajectory has been impacted due to industry-wide elevated cancellation rates and a broad slowdown in new clinical trial starts.
Funding EnvironmentThe change in customer dynamics tied to the choppier funding environment adds a greater element of uncertainty to Medpace's near-term results.
---
Ownership Overview
19.36% Insiders
24.59% Mutual Funds
28.26% Other Institutional Investors
7.21% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MEDP FAQ
What was Medpace Holdings Inc’s price range in the past 12 months?
Medpace Holdings Inc lowest stock price was $302.01 and its highest was $459.77 in the past 12 months.
What is Medpace Holdings Inc’s market cap?
Medpace Holdings Inc’s market cap is $9.52B.
When is Medpace Holdings Inc’s upcoming earnings report date?
Medpace Holdings Inc’s upcoming earnings report date is Apr 21, 2025 which is in 21 days.
How were Medpace Holdings Inc’s earnings last quarter?
Medpace Holdings Inc released its earnings results on Feb 10, 2025. The company reported $3.67 earnings per share for the quarter, beating the consensus estimate of $2.939 by $0.731.
Is Medpace Holdings Inc overvalued?
According to Wall Street analysts Medpace Holdings Inc’s price is currently Undervalued.
Does Medpace Holdings Inc pay dividends?
Medpace Holdings Inc does not currently pay dividends.
What is Medpace Holdings Inc’s EPS estimate?
Medpace Holdings Inc’s EPS estimate is 3.05.
How many shares outstanding does Medpace Holdings Inc have?
Medpace Holdings Inc has 30,466,806 shares outstanding.
What happened to Medpace Holdings Inc’s price movement after its last earnings report?
Medpace Holdings Inc reported an EPS of $3.67 in its last earnings report, beating expectations of $2.939. Following the earnings report the stock price went down -7.517%.
Which hedge fund is a major shareholder of Medpace Holdings Inc?
Currently, no hedge funds are holding shares in MEDP
---
Medpace Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$352.67 (12.90% Upside)
$352.67 (12.90% Upside)
Blogger Sentiment
Bullish
MEDP Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 80.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.71%
12-Months-Change
Fundamentals
Return on Equity
58.41%
Trailing 12-Months
Asset Growth
26.80%
Trailing 12-Months
Company Description
Medpace Holdings Inc
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.
---
MEDP Company Deck
---
MEDP Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook. While the company achieved significant revenue and income growth in 2024, challenges such as a weak book-to-bill ratio, decrease in new business awards, and elevated cancellations pose concerns for 2025. The guidance for 2025 indicates a cautious outlook with flat to modest revenue growth expected.Read More>---
MEDP Revenue Breakdown
98.00% U.S.
2.00% Other
---
MEDP Stock 12 Month Forecast
Average Price Target
$352.67
▲(12.90% Upside)
Technical Analysis
Best Analysts Covering MEDP
1 Year
1 Year Success Rate
0/6 ratings generated profit
1 Year Average Return
-9.97%
reiterated a buy rating 28 days ago
Copying Charles Rhyee's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -9.97% per trade.
---